Litcius/Paper detail

Efficacy of Ustekinumab for Active Perianal Fistulizing Crohn Disease: A Double-Center Cohort Study

Mohamed Attauabi, Johan Burisch, Jakob Benedict Seidelin

2020Inflammatory Bowel Diseases15 citationsDOI

Abstract

This double-center cohort study found a high short-term and long-term efficacy of ustekinumab for perianal fistulizing Crohn disease that was also well tolerated.

Topics & Concepts

UstekinumabMedicineCrohn's diseaseCohortCohort studyInternal medicineDermatologyGastroenterologyDiseaseAdalimumabInflammatory Bowel DiseaseAutoimmune and Inflammatory DisordersDiverticular Disease and Complications
Efficacy of Ustekinumab for Active Perianal Fistulizing Crohn Disease: A Double-Center Cohort Study | Litcius